Adalimumab

Stelara and Humira demonstrated rapid onset of action and effectiveness in the treatment of patients with moderate to severe Crohn’s disease, Bruce Sands, MD, Icahn School of Medicine, told Healio Gastroenterology.

Upadacitinib continues to maintain higher levels of clinical response, compared with adalimumab, in patients with rheumatoid arthritis through 3 years, according to data presented at the EULAR 2021 Virtual Congress.

Switching to bimekizumab resulted in better outcomes among certain patients with psoriasis who did not respond as well to adalimumab, according to results presented at AAD VMX 2021.

Patients with psoriasis who switched from Humira to adalimumab biosimilars for nonmedical reasons had similar drug retention as those who stayed on the originator, according to a study.

A daily 30 mg dose of upadacitinib — but not the 15 mg dose — is superior to adalimumab at improving the signs and symptoms of psoriatic arthritis among patients with inadequate response to non-biologic disease-modifying antirheumatic drugs.

Upadacitinib is equivalent or superior to adalimumab in improving patient-reported outcomes among those with rheumatoid arthritis and an inadequate response to methotrexate, according to data published in Rheumatology.

The adalimumab biosimilar CT-P17 demonstrates equivalent efficacy, and comparable safety and immunogenicity, to its reference product in patients with rheumatoid arthritis, according to data published in Arthritis Research & Therapy.

Filgotinib improves rheumatoid arthritis signs, symptoms and physician function, and inhibits radiographic progression, all while being well-tolerated in patients with an insufficient response to methotrexate, according to data.

Although secukinumab performs similarly to adalimumab in patients with spondyloarthritis who failed their first biological treatment, adalimumab proved superior in those who failed multiple biologics, according to data.

Among patients with rheumatoid arthritis, herpes zoster is more common in those treated with upadacitinib than with adalimumab plus methotrexate or with methotrexate alone, according to a speaker at ACR Convergence 2020.